Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities.
PET Clin
; 17(1): 13-29, 2022 Jan.
Article
in En
| MEDLINE
| ID: mdl-34809862
ABSTRACT
Almost 1 in 10 individuals can suffer from one of many rare diseases (RDs). The average time to diagnosis for an RD patient is as high as 7 years. Artificial intelligence (AI)-based positron emission tomography (PET), if implemented appropriately, has tremendous potential to advance the diagnosis of RDs. Patient advocacy groups must be active stakeholders in the AI ecosystem if we are to avoid potential issues related to the implementation of AI into health care. AI medical devices must not only be RD-aware at each stage of their conceptualization and life cycle but also should be trained on diverse and augmented datasets representative of the end-user population including RDs. Inability to do so leads to potential harm and unsustainable deployment of AI-based medical devices (AIMDs) into clinical practice.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Artificial Intelligence
/
Rare Diseases
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
PET Clin
Year:
2022
Document type:
Article
Affiliation country:
United States